Result for
Tag: adverse effects
June 3, 2021
Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals
The Pfizer-BioNTech vaccine elicited worse local and systemic reactions among individuals with a history of allergy in an online survey of vaccinated medical professionals in Poland (n=1,808). However, no severe allergic reactions were reported. Local redness (17% vs 11%), pain (86% vs 80%), and swelling (19% vs 13%) after the first dose and vomiting (3%…
May 20, 2021
Thrombocytopenia Including Immune Thrombocytopenia after Receipt of MRNA COVID-19 Vaccines Reported to the Vaccine Adverse Event Reporting System (VAERS)
An analysis of reported adverse events following vaccination with an mRNA COVID-19 vaccine indicates that the reported number of thrombocytopenia cases does not suggest a safety concern attributable to mRNA COVID-19 vaccines at this time. Fifteen cases of thrombocytopenia were identified among 18,841,309 doses of Pfizer-BioNTech vaccine and 13 cases among 16,260,102 doses of Moderna…
April 29, 2021
Prothrombotic Immune Thrombocytopenia after COVID-19 Vaccine
5 cases of prothrombotic immune thrombocytopenia were identified in Germany at 5 to 11 days after receiving the first dose of the Oxford-AstraZeneca vaccine. Clinical manifestations included cerebral venous sinus thrombosis, splanchnic vein thrombosis, arterial cerebral thromboembolism, and thrombotic microangiopathy. Anti-PF4/polyanion antibodies were detected in all patients. After anticoagulation alone or in combination with eculizumab…
Complications of COVID-19 Nasopharyngeal Swab Test
Complications requiring emergency department treatment from nasopharyngeal swab sampling for SARS-CoV-2 PCR tests occurred in 1.24 per 100,000 tests during a 7-month period in Helsinki University Hospital, Finland. Out of over 640,000 PCR tests performed, 8 complication-related visits were identified in patients presenting to the emergency department (4 nasal bleeds, of which half were potentially…
April 27, 2021
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
The Advisory Committee on Immunization Practices (ACIP) reaffirmed its interim recommendation for use of the Johnson & Johnson vaccine in all persons aged ≥18 years on April 23, 2021 and recommended including a warning that rare clotting events may occur in female vaccine recipients aged 18-49 years. The updated recommendations follow the recommended pause by…
March 9, 2021
Acute Allergic Reactions to MRNA COVID-19 Vaccines
Among employees of Mass General Brigham (MGB), a Boston-based hospital and physicians network, who received their first dose of either the Pfizer-BioNTech or Moderna vaccine (n=64,900), acute allergic reactions of any type were reported by 1,365 employees overall (2.1%) and anaphylaxis was reported by 16 employees (2.5 cases per 10,000 vaccinations).. Among those reporting anaphylaxis,…